Carregando...
Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer
IMPORTANCE: The BEACON trial showed that combination therapy with encorafenib (BRAF inhibitor) and cetuximab (EGFR inhibitor) was associated with prolonged overall survival compared with standard chemotherapy in patients with metastatic BRAF variant colorectal cancer. However, the cost-effectiveness...
Na minha lista:
| Publicado no: | JAMA Netw Open |
|---|---|
| Principais autores: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Medical Association
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7804917/ https://ncbi.nlm.nih.gov/pubmed/33433598 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.33441 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|